Institut National De La Sante Et De La Recherche Medicale

Assistance Publique-hopitaux De Paris

Institut Gustave Roussy

Centre Henri Becquerel

UniversitÉ Paris Descartes

Université Paris—sud

Université Pierre Et Marie Curie (Paris 6)

Université Pierre Et Marie Curie

Université Paris-Sud 11

Franck Viguie

William Vainchenker

Olivier Bernard

Michaela Fontenay

Christian Bastard

Francois Delhommeau

François Delhommeau

The present invention concerns an in vitro method for diagnosing a myeloid tumour or a lymphoid tumour in a subject, which comprises the step of analyzing a biological sample from said subject by (i) detecting the presence of a mutation in the Ten Eleven Translocation protein family member 2 gene (TET2) coding for the polypeptide having the sequence SEQ ID NO: 2, and/or (ii) analyzing the expression of the TET2 gene; wherein the detection of such a TET2 mutation, of the absence of expression of TET2 or of the expression of a truncated TET2 is indicative of a subject developing or predisposed to develop a myeloid tumour or a lymphoid tumour.

TET2 as a diagnostic and pronostic marker in hematopoietic neoplasms

TET2 as a diagnostic and prognostic marker in hematopoietic neoplasms

The present invention concerns an in vitro method for diagnosing a myeloid tumor or a lymphoid tumor in a subject, which comprises the step of analyzing a biological sample from said subject by (i) detecting the presence of a mutation in the Ten Eleven Translocation protein family member 2 gene (TET2) coding for the polypeptide having the sequence SEQ ID NO:2, and/or (ii) analyzing the expression of the TET2 gene; wherein the detection of such a TET2 mutation, of the absence of expression of TET2 or of the expression of a truncated TET2 is indicative of a subject developing or predisposed to develop a myeloid tumor or a lymphoid tumor.

TET2 as a new diagnostic and pronostic marker in hematopoietic neoplasms

Growing community of inventors

Deuil la Barre, France

Franck Viguie